אבוסינאגיס 50 מ"ג

Pays: Israël

Langue: hébreu

Source: Ministry of Health

Ingrédients actifs:

PALIVIZUMAB 50 MG

Disponible depuis:

ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL

Code ATC:

J06BB16

forme pharmaceutique:

POWDER FOR SOLUTION FOR INJECTION

Mode d'administration:

I.M

Fabriqué par:

ABBVIE S.R.L., ITALY

Groupe thérapeutique:

PALIVIZUMAB

indications thérapeutiques:

Is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV). Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

Date de l'autorisation:

2010-07-01